메뉴 건너뛰기




Volumn 59, Issue 2, 2014, Pages 308-313

Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology

Author keywords

Advanced NSCLC; Genotype; Histotype; Treatment individualization

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED;

EID: 84908396340     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2014.08.008     Document Type: Review
Times cited : (22)

References (44)
  • 1
    • 80053639884 scopus 로고    scopus 로고
    • 2011 Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer
    • October
    • Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, et al. 2011 focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011;29(October (28)):3825-31.
    • (2011) J Clin Oncol , vol.29 , Issue.28 , pp. 3825-3831
    • Azzoli, C.G.1    Temin, S.2    Aliff, T.3    Baker, S.4    Brahmer, J.5    Johnson, D.H.6
  • 2
    • 84866597083 scopus 로고    scopus 로고
    • Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • October
    • Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(October (Suppl. 7)). vii56-64.
    • (2012) Ann Oncol , vol.23 , pp. vii56-vii64
    • Peters, S.1    Adjei, A.A.2    Gridelli, C.3    Reck, M.4    Kerr, K.5    Felip, E.6
  • 3
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • September
    • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(September (10)):947-57.
    • (2009) N Engl J Med , vol.361 , Issue.10 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3    Yang, C.H.4    Chu, D.T.5    Saijo, N.6
  • 4
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
    • August
    • Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12(August (8)):735-42.
    • (2011) Lancet Oncol , vol.12 , Issue.8 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3    Feng, J.4    Liu, X.Q.5    Wang, C.6
  • 5
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
    • March
    • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(March (3)):239-46.
    • (2012) Lancet Oncol , vol.13 , Issue.3 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3    Vergnenegre, A.4    Massuti, B.5    Felip, E.6
  • 6
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
    • February
    • Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11(February (2)):121-8.
    • (2010) Lancet Oncol , vol.11 , Issue.2 , pp. 121-128
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3    Negoro, S.4    Okamoto, I.5    Tsurutani, J.6
  • 7
    • 84861976809 scopus 로고    scopus 로고
    • First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
    • April
    • Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30(April (10)):1122-8.
    • (2012) J Clin Oncol , vol.30 , Issue.10 , pp. 1122-1128
    • Han, J.Y.1    Park, K.2    Kim, S.W.3    Lee, D.H.4    Kim, H.Y.5    Kim, H.T.6
  • 8
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • June
    • Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(June (25)):2380-8.
    • (2010) N Engl J Med , vol.362 , Issue.25 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3    Sugawara, S.4    Oizumi, S.5    Isobe, H.6
  • 9
    • 84884736973 scopus 로고    scopus 로고
    • Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    • September
    • Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31(September (27)):3327-34.
    • (2013) J Clin Oncol , vol.31 , Issue.27 , pp. 3327-3334
    • Sequist, L.V.1    Yang, J.C.2    Yamamoto, N.3    O'Byrne, K.4    Hirsh, V.5    Mok, T.6
  • 10
    • 84877291745 scopus 로고    scopus 로고
    • Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
    • May
    • Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105(May (9)):595-605.
    • (2013) J Natl Cancer Inst , vol.105 , Issue.9 , pp. 595-605
    • Lee, C.K.1    Brown, C.2    Gralla, R.J.3    Hirsh, V.4    Thongprasert, S.5    Tsai, C.M.6
  • 11
    • 84884659258 scopus 로고    scopus 로고
    • Lux-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung
    • 2013 ASCO Annual Meeting
    • Wu YL, Zhou C, Hu C-P, Feng JF, Lu S, Huang Y, et al. Lux-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. 2013 ASCO Annual Meeting. J Clin Oncol 2013;8016.
    • (2013) J Clin Oncol , pp. 8016
    • Wu, Y.L.1    Zhou, C.2    Hu, C.-P.3    Feng, J.F.4    Lu, S.5    Huang, Y.6
  • 12
    • 20044364940 scopus 로고    scopus 로고
    • Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    • March
    • Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97(March (5)):339-46.
    • (2005) J Natl Cancer Inst , vol.97 , Issue.5 , pp. 339-346
    • Shigematsu, H.1    Lin, L.2    Takahashi, T.3    Nomura, M.4    Suzuki, M.5    Wistuba, I.I.6
  • 13
    • 28844449401 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
    • November
    • Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23(November (31)):8081-92.
    • (2005) J Clin Oncol , vol.23 , Issue.31 , pp. 8081-8092
    • Bell, D.W.1    Lynch, T.J.2    Haserlat, S.M.3    Harris, P.L.4    Okimoto, R.A.5    Brannigan, B.W.6
  • 14
    • 69949186250 scopus 로고    scopus 로고
    • Screening for epidermal growth factor receptor mutations in lung cancer
    • September
    • Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361(September (10)):958-67.
    • (2009) N Engl J Med , vol.361 , Issue.10 , pp. 958-967
    • Rosell, R.1    Moran, T.2    Queralt, C.3    Porta, R.4    Cardenal, F.5    Camps, C.6
  • 15
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • July
    • Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(July (21)):3543-51.
    • (2008) J Clin Oncol , vol.26 , Issue.21 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3    Biesma, B.4    Vansteenkiste, J.5    Manegold, C.6
  • 16
    • 78651066494 scopus 로고    scopus 로고
    • Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer
    • January
    • Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6(January (1)):64-70.
    • (2011) J Thorac Oncol , vol.6 , Issue.1 , pp. 64-70
    • Scagliotti, G.1    Brodowicz, T.2    Shepherd, F.A.3    Zielinski, C.4    Vansteenkiste, J.5    Manegold, C.6
  • 17
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • December
    • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(December (24)):2542-50.
    • (2006) N Engl J Med , vol.355 , Issue.24 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowlati, A.6
  • 18
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
    • March
    • Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27(March (8)):1227-34.
    • (2009) J Clin Oncol , vol.27 , Issue.8 , pp. 1227-1234
    • Reck, M.1    Von Pawel, J.2    Zatloukal, P.3    Ramlau, R.4    Gorbounova, V.5    Hirsh, V.6
  • 19
    • 77956266591 scopus 로고    scopus 로고
    • Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer
    • September
    • Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;5(September (9)):1416-23.
    • (2010) J Thorac Oncol , vol.5 , Issue.9 , pp. 1416-1423
    • Sandler, A.1    Yi, J.2    Dahlberg, S.3    Kolb, M.M.4    Wang, L.5    Hambleton, J.6
  • 20
    • 77951473661 scopus 로고    scopus 로고
    • Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL)
    • September
    • Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21(September (9)):1804-9.
    • (2010) Ann Oncol , vol.21 , Issue.9 , pp. 1804-1809
    • Reck, M.1    Von Pawel, J.2    Zatloukal, P.3    Ramlau, R.4    Gorbounova, V.5    Hirsh, V.6
  • 21
    • 77955268612 scopus 로고    scopus 로고
    • Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): A phase 4 study
    • August
    • Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010;11(August (8)):733-40.
    • (2010) Lancet Oncol , vol.11 , Issue.8 , pp. 733-740
    • Crinò, L.1    Dansin, E.2    Garrido, P.3    Griesinger, F.4    Laskin, J.5    Pavlakis, N.6
  • 23
    • 0037420202 scopus 로고    scopus 로고
    • Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
    • March
    • Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95(March (5)):362-72.
    • (2003) J Natl Cancer Inst , vol.95 , Issue.5 , pp. 362-372
    • Gridelli, C.1    Perrone, F.2    Gallo, C.3    Cigolari, S.4    Rossi, A.5    Piantedosi, F.6
  • 24
    • 0037028750 scopus 로고    scopus 로고
    • Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial
    • February
    • Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94(February (3)):173-81.
    • (2002) J Natl Cancer Inst , vol.94 , Issue.3 , pp. 173-181
    • Langer, C.J.1    Manola, J.2    Bernardo, P.3    Kugler, J.W.4    Bonomi, P.5    Cella, D.6
  • 25
    • 80052964872 scopus 로고    scopus 로고
    • Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
    • September
    • Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378(September (9796)):1079-88.
    • (2011) Lancet , vol.378 , Issue.9796 , pp. 1079-1088
    • Quoix, E.1    Zalcman, G.2    Oster, J.P.3    Westeel, V.4    Pichon, E.5    Lavolé, A.6
  • 26
    • 77953541527 scopus 로고    scopus 로고
    • Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
    • June
    • Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11(June (6)):521-9.
    • (2010) Lancet Oncol , vol.11 , Issue.6 , pp. 521-529
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3    Cicenas, S.4    Szczésna, A.5    Juhász, E.6
  • 27
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study
    • October
    • Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374(October (9699)):1432-40.
    • (2009) Lancet , vol.374 , Issue.9699 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3    Kim, J.H.4    Krzakowski, M.5    Laack, E.6
  • 28
    • 84857507055 scopus 로고    scopus 로고
    • Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial
    • March
    • Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13(March (3)):247-55.
    • (2012) Lancet Oncol , vol.13 , Issue.3 , pp. 247-255
    • Paz-Ares, L.1    De Marinis, F.2    Dediu, M.3    Thomas, M.4    Pujol, J.L.5    Bidoli, P.6
  • 29
    • 84885924300 scopus 로고    scopus 로고
    • PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    • August
    • Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31(August (23)):2895-902.
    • (2013) J Clin Oncol , vol.31 , Issue.23 , pp. 2895-2902
    • Paz-Ares, L.G.1    De Marinis, F.2    Dediu, M.3    Thomas, M.4    Pujol, J.L.5    Bidoli, P.6
  • 31
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • May
    • Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(May (9)):1589-97.
    • (2004) J Clin Oncol , vol.22 , Issue.9 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3    Pereira, J.R.4    De Marinis, F.5    Von Pawel, J.6
  • 32
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • May
    • Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(May (10)):2095-103.
    • (2000) J Clin Oncol , vol.18 , Issue.10 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3    Mattson, K.4    Gralla, R.5    O'Rourke, M.6
  • 33
    • 17844390172 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
    • April
    • Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23(April (11)):2556-68.
    • (2005) J Clin Oncol , vol.23 , Issue.11 , pp. 2556-2568
    • Pao, W.1    Miller, V.A.2
  • 34
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • October 29-November 4
    • Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(October 29-November 4 (9496)):1527-37.
    • (2005) Lancet , vol.366 , Issue.9496 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3    Rodrigues Pereira, J.4    Ciuleanu, T.5    Von Pawel, J.6
  • 35
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
    • November
    • Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372(November (9652)):1809-18.
    • (2008) Lancet , vol.372 , Issue.9652 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3    Socinski, M.A.4    Gervais, R.5    Wu, Y.L.6
  • 36
    • 77649222572 scopus 로고    scopus 로고
    • Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial
    • February
    • Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28(February (5)):744-52.
    • (2010) J Clin Oncol , vol.28 , Issue.5 , pp. 744-752
    • Douillard, J.Y.1    Shepherd, F.A.2    Hirsh, V.3    Mok, T.4    Socinski, M.A.5    Gervais, R.6
  • 37
    • 52049125250 scopus 로고    scopus 로고
    • Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
    • September
    • Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26(September (26)):4244-52.
    • (2008) J Clin Oncol , vol.26 , Issue.26 , pp. 4244-4252
    • Maruyama, R.1    Nishiwaki, Y.2    Tamura, T.3    Yamamoto, N.4    Tsuboi, M.5    Nakagawa, K.6
  • 38
    • 84880570204 scopus 로고    scopus 로고
    • Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study
    • August
    • Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013;119(August (15)):2754-64.
    • (2013) Cancer , vol.119 , Issue.15 , pp. 2754-2764
    • Karampeazis, A.1    Voutsina, A.2    Souglakos, J.3    Kentepozidis, N.4    Giassas, S.5    Christofillakis, C.6
  • 39
    • 84857501696 scopus 로고    scopus 로고
    • Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study
    • March
    • Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13(March (3)):300-8.
    • (2012) Lancet Oncol , vol.13 , Issue.3 , pp. 300-308
    • Ciuleanu, T.1    Stelmakh, L.2    Cicenas, S.3    Miliauskas, S.4    Grigorescu, A.C.5    Hillenbach, C.6
  • 40
    • 84883055532 scopus 로고    scopus 로고
    • Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial
    • September
    • Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14(September (10)):981-8.
    • (2013) Lancet Oncol , vol.14 , Issue.10 , pp. 981-988
    • Garassino, M.C.1    Martelli, O.2    Broggini, M.3    Farina, G.4    Veronese, S.5    Rulli, E.6
  • 41
    • 84866934606 scopus 로고    scopus 로고
    • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study
    • October
    • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13(October (10)):1011-9.
    • (2012) Lancet Oncol , vol.13 , Issue.10 , pp. 1011-1019
    • Camidge, D.R.1    Bang, Y.J.2    Kwak, E.L.3    Iafrate, A.J.4    Varella-Garcia, M.5    Fox, S.B.6
  • 42
    • 84865431278 scopus 로고    scopus 로고
    • Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)
    • 2012 ASCO Annual Meeting
    • Kim D-W, Ahn M-J, Shi Y, De Pas TM, Yang P-C, Riely GJ, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). 2012 ASCO Annual Meeting. J Clin Oncol 2012;7533.
    • (2012) J Clin Oncol , pp. 7533
    • Kim, D.-W.1    Ahn, M.-J.2    Shi, Y.3    De Pas, T.M.4    Yang, P.-C.5    Riely, G.J.6
  • 43
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    • June
    • Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368(June (25)):2385.
    • (2013) N Engl J Med , vol.368 , Issue.25 , pp. 2385
    • Shaw, A.T.1    Kim, D.W.2    Nakagawa, K.3    Seto, T.4    Crinó, L.5    Ahn, M.J.6
  • 44
    • 84880917028 scopus 로고    scopus 로고
    • Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    • July
    • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8(July (7)):823-59.
    • (2013) J Thorac Oncol , vol.8 , Issue.7 , pp. 823-859
    • Lindeman, N.I.1    Cagle, P.T.2    Beasley, M.B.3    Chitale, D.A.4    Dacic, S.5    Giaccone, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.